CervoMed Inc. (CRVO) Income Statement
CRVO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCRVO revenue and net income
Where CRVO's revenue goes
2025Each bar shows an amount and its share of revenue. CRVO kept −673.1% of revenue as net income.
CRVO profit margins
CRVO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −58.9% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CRVO quarterly EPS vs estimates
CervoMed beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 6, 2026 (estimate $-0.61).
CRVO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $18.8M | $8.4M | $1.3M | $93,416 | $103,168 | $97,915 | $110,371 | $67,981 | $25,342 |
| Gross profit | — | −$9.1M | −$1.3M | −$1.3M | −$93,416 | −$103,168 | −$97,915 | −$110,000 | −$67,981 | −$25,342 |
| Research & development | $21.8M | $18.8M | $8.4M | $7.2M | $8.5M | $9.4M | $6.6M | $5.8M | $5.1M | $6.3M |
| Sales, general & admin | $10.5M | $9.2M | $6.5M | $8.7M | $7.4M | $6.4M | $5.4M | — | — | — |
| Total operating expenses | $28.3M | $18.2M | $7.8M | $16.0M | $24.7M | $15.9M | $11.5M | $11.9M | $11.3M | $14.8M |
| Operating income | −$28.3M | −$18.2M | −$7.8M | −$16.0M | −$24.7M | −$16.0M | −$11.6M | −$12.0M | −$11.3M | −$14.9M |
| Interest income | $1.3M | $1.9M | $219,430 | $380,752 | $137,487 | $114,257 | — | — | — | — |
| Interest expense | — | — | $0 | $587 | — | — | — | — | $2.9M | $29,686 |
| Income before taxes | −$27.0M | −$16.3M | −$2.2M | −$15.6M | −$24.5M | −$15.9M | −$11.5M | −$18.8M | −$2.4M | −$18.4M |
| Income taxes | — | — | $800,005 | −$3.5M | −$443,893 | −$1.7M | $332,885 | −$437,000 | −$1.1M | −$365,000 |
| Net income | −$27.0M | −$16.3M | −$2.2M | −$15.6M | −$24.1M | −$14.2M | −$11.8M | −$18.4M | −$1.4M | −$18.0M |
| EBITDA | −$27.0M | −$16.3M | −$2.2M | −$3.5M | −$15.9M | −$15.8M | −$11.4M | −$18.7M | $566,010 | −$18.3M |
| EPS (diluted) | −$2.98 | −$2.03 | −$3.29 | −$10.48 | −$18.75 | −$22.50 | −$132.00 | −$328.73 | −$104.20 | −$1125.57 |
| Gross margin | — | −93.0% | −18.1% | — | — | — | — | — | — | — |
| Operating margin | −706.2% | −187.2% | −109.3% | — | — | — | — | — | — | — |
| Net margin | −673.1% | −167.3% | −30.4% | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8,726 | $322,569 | $1.8M | $1.9M | $2.2M | $1.9M | $3.3M | $2.3M | $2.5M | $1.5M |
| Cost of revenue | — | — | — | $0 | $5.1M | $4.8M | $7.1M | $5.1M | $8.0M | $2.8M | $2.9M | $1.8M |
| Gross profit | — | — | — | $322,569 | −$3.4M | −$2.9M | −$4.9M | −$3.2M | $3.3M | −$467,000 | −$365,000 | −$265,000 |
| Research & development | $4.3M | $5.1M | $5.8M | $6.0M | $5.1M | $4.8M | $7.1M | $5.1M | $3.8M | $2.8M | $2.9M | $1.8M |
| Sales, general & admin | $2.4M | $3.0M | $2.5M | $2.3M | $3.3M | $2.4M | $2.3M | $2.2M | $2.5M | $2.1M | $2.1M | $2.4M |
| Total operating expenses | $6.7M | $8.1M | $8.3M | $8.4M | $6.6M | $5.3M | $7.2M | $5.4M | $3.0M | $2.6M | $2.5M | $2.7M |
| Operating income | −$6.7M | −$8.1M | −$8.3M | −$8.0M | −$6.6M | −$5.3M | −$7.2M | −$5.4M | −$3.0M | −$2.6M | −$2.5M | −$2.7M |
| Interest income | $104,897 | $147,387 | $240,938 | $318,787 | $368,127 | $408,985 | $532,181 | $646,172 | $678,441 | $80,633 | $118,652 | $47,667 |
| Income before taxes | −$6.6M | −$8.0M | −$8.1M | −$7.7M | −$6.3M | −$4.9M | −$6.7M | −$4.8M | −$2.3M | −$2.5M | −$2.4M | $2.2M |
| Income taxes | — | — | — | — | — | — | — | — | $1 | $2 | $800,000 | −$2.7M |
| Net income | −$6.6M | −$8.0M | −$8.1M | −$7.7M | −$6.3M | −$4.9M | −$6.7M | −$4.8M | −$2.3M | −$2.5M | −$2.4M | $2.2M |
| EBITDA | −$6.6M | −$8.0M | −$8.1M | −$7.7M | −$6.3M | −$4.9M | −$6.7M | −$4.8M | −$2.3M | −$2.5M | $3.2M | $2.2M |
| EPS (diluted) | −$0.64 | −$0.86 | −$0.88 | −$0.84 | −$0.70 | −$0.56 | −$0.80 | −$0.55 | −$0.27 | −$0.41 | −$0.38 | $0.65 |
| Gross margin | — | — | — | 100.0% | −190.6% | −152.3% | −227.8% | −164.2% | 100.0% | −19.9% | −14.7% | −17.4% |
| Operating margin | — | — | −95,479.2% | −2,493.8% | −376.4% | −276.6% | −334.9% | −278.2% | −91.1% | −110.6% | −99.6% | −175.3% |
| Net margin | — | — | −92,680.4% | −2,395.3% | −356.1% | −255.3% | −310.2% | −245.0% | −70.4% | −107.1% | −94.8% | 140.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CRVO's financial statements (latest annual report filed March 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CRVO financial results
In fiscal year 2025 (ended December 31, 2025), CervoMed reported revenue of $4.0 million, down 58.9% from the year before. It had a net loss of $27.0 million, a net profit margin of −673.1%. Diluted earnings per share came to −$2.98.
See the CRVO stock overview for the latest quote and news, or the CRVO chart for price history and technical indicators.
CRVO income statement FAQ
What is CervoMed's annual revenue?
CervoMed reported total revenue of $4.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 58.9% from $9.7 million the previous year.
Is CervoMed profitable?
No. CervoMed reported a net loss of $27.0 million in fiscal 2025, a net profit margin of −673.1%; its operating margin was −706.2%.
How much does CervoMed spend on research and development?
CervoMed spent $21.8 million on research and development in fiscal 2025, 544.5% of revenue.
What are CervoMed's earnings per share?
CervoMed earned $-2.98 per diluted share in fiscal 2025, compared with $-2.03 a year earlier.
When will CervoMed report its next earnings?
CervoMed is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does CervoMed's fiscal year end?
CervoMed's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 13, 2026.